Since its founding in 2005, Precision Health Economics (PHE), a part of Precision for Value, has earned a reputation as a world-renowned, cutting-edge consultancy firm, specializing in health policy, economics, and analytics. PHE leverages the expertise of policy analysts, economists, epidemiologists, clinicians, and academics from elite universities to advance research on the most complex healthcare questions.
PHE has a global reputation for delivering results that have strategic and practical applications, generating academic publications in the world’s leading research journals, and leading formal public debates in prestigious, closely watched forums.
PHE’s research focuses on attributes of value important to all healthcare constituencies; helping pharmaceutical, biologic and health care technology companies determine product value, cost-benefit and pricing, starting early in clinical development through global payer submissions.
Life science companies and policymakers worldwide turn to PHE to shape strategy, inform key healthcare decisions, and produce effective changes in public policy through insightful, issue-driven research.
Decision-analytic models integrate the available evidence of interventions in a transparent manner to evaluate their risk-benefit, economic value, and public health impact. PHE produces evidence-based decision-analytic models to assess risk-benefit, economic value, and the public health impact of medical interventions developed in alignment with the requirements of HTA and reimbursement bodies. Decision models frequently require extrapolations beyond the time-horizon, interventions, outcomes, and settings observed in the available individual studies.
Why cost-effectiveness modeling for HTA? In many jurisdictions, decisions regarding the reimbursement of a drug are not limited to a comparative assessment of clinical outcomes, but involve an assessment of its cost-effectiveness as well. An individual study hardly ever provides information regarding all aspects informing the cost-effectiveness decision of the competing interventions.
PHE has pioneered the development of novel simulation techniques for modeling the effects of future health technologies, health trends, and commercial strategies, all based on real-world data. PHE also conducts decision-analytic models – to evaluate risk-benefit, cost-effectiveness, financial impact, and other outcomes -- with unique depth and rigor.
Precision Health Economics has not received any reviews.
Precision Health Economics has not received any endorsements.